Description

Anoro Ellipta (umeclidinium) powder for inhalation 55 mcg/22 mcg/dose 30 dose №1

Ingredients:

Anoro Ellipta contains umeclidinium, which is a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). These ingredients work together to relax the muscles around the airways, making it easier to breathe.

Dosage:

The recommended dosage is one inhalation once daily. Each inhalation delivers 55 mcg of umeclidinium and 22 mcg of vilanterol.

Indications:

Anoro Ellipta is indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Contraindications:

Anoro Ellipta is contraindicated in patients with severe hypersensitivity to umeclidinium, vilanterol, or any of the ingredients in the formulation.

Directions:

Anoro Ellipta should be used exactly as prescribed by your healthcare provider. Do not exceed the recommended dose, and do not use it for sudden breathing problems.

Scientific Evidence:

Studies have shown that the combination of umeclidinium and vilanterol in Anoro Ellipta provides superior bronchodilation compared to either component alone. This dual bronchodilator therapy has been proven to improve lung function and reduce exacerbations in patients with COPD.

Additional Information:

It is important to note that Anoro Ellipta is not a rescue medication and should not be used for the treatment of acute bronchospasm. If sudden breathing problems occur, a fast-acting inhaler should be used.

Pharmacologically, umeclidinium works by blocking the action of acetylcholine at muscarinic receptors in the airway smooth muscle, leading to bronchodilation. Vilanterol, on the other hand, stimulates the beta2-adrenergic receptors, resulting in relaxation of the airway muscles. This combined mechanism of action helps to improve airflow and reduce symptoms in patients with COPD.

Clinical trials have demonstrated the efficacy of Anoro Ellipta in improving lung function and quality of life in patients with COPD. In a study published in the International Journal of Chronic Obstructive Pulmonary Disease, the combination therapy of umeclidinium and vilanterol showed significant improvements in FEV1 (forced expiratory volume in 1 second) compared to placebo.